GERMANY – VisionHealth, a Munich, Germany-based digital therapeutics (DTx) company focused on enhancing inhaled treatment of chronic lung diseases, raised €3M in Pre-Series A funding.
The round was led by DB Speciality Invest.Founded in 2017 and led by Dr. Sabine Haeussermann, CEO, VisionHealth focuses on digital therapy support for respiratory diseases. In cooperation with research institutions and selected industry partners, medical experts and IT experts, the company develops digital health solutions enabling sustainable improvements to existing standard therapies for patients with chronic lung diseases like asthma and COPD. The company intends to use the funds to to finance extended COPD and asthma study for market preparation of Kata®, an innovative digital therapeutic for improved inhalation. Funds will be used for EU and U.S. regulatory approval and commercial launch of the Kata app in Germany and select European markets. The aim of the app for patients is to optimize the drug inhalation therapy of chronic lung diseases through digital support by help of augmented reality using the smartphone camera for immediate feedback and correction. 27/02/2023
